Sai Life Sciences Ltd News

Jefferies names Sai Life Sciences top CRDMO pick, lists 10 reasons to buy

The brokerage noted that Sai Life remains relatively small compared with its addressable market, with FY25 sales of about $200 million, providing significant room for expansion

Sai Life hits record high in weak market; rebounds 5% from day's low

Supported by solid demand, disciplined execution, and capex programs progressing as planned, Sai Life management remains confident in sustaining positive growth momentum.

Sai Life soars 25% in 5 weeks, hits record high in weak market; here's why

ICRA expects Sai Life Sciences to maintain strong growth momentum over the medium term on the back of a healthy growth outlook for the industry, good product mix and deepening customer engagement.

Sai Life Sciences shares jump 8% as Q3 profit surges 86% YoY

Sai Life Sciences has invested ₹405 crore in capital expenditure so far, against its planned outlay of ₹700 crore for FY26

Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs

Sai Life rallies 5%, hits all-time high; what's driving pharma stock?

In H1FY26, total revenue of the Sai Life Sciences increased by 53% YoY at ₹1,034 crore, driven by healthy growth across both the CRO and the CDMO business.

Sai Life Sciences gains 4%, stock snaps 4-day losing streak; here's why

Sai Life stock outlook: Given its high-growth outlook and improving profitability, analysts at JM Financial value the stock at 32x Sept 2027 EBITDA to arrive at a target price of ₹1,197.

MFs top picks: Stake up 800 bps in these 3 science innovators; do you own?

Mutual Funds increased holding by up to 800 basis points in Clean Science and Technology, Sai Life Sciences and Cohance Lifesciences in September quarter. Here's a technical outlook on these 3 stocks.